Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (412)	4/25/1999 10:46:00 PM
From: Miljenko Zuanic	Respond to of 550

SMH' <<Your statement makes more sense to me than what the co. said in either the cc or the release. >> It is my statement, so be careful. :) It is my opinion that SUGEN EU should be financed separately from SUGEN US. Also US SUGN should have financial support (from licensing and up-front fee) as well as free clinical trials in EU. Which will support and complement US trials (for 5416 and 6668). Where is real true, balance, I do not know. Regards the leverage and off-label potential, if 5416 KS trials proceed as planed (by SUGN), than drug may be approved in 2Q/3Q 2000, with plenty of off-label usage. Which is the faster drug development time than for any cancer drug which I saw up to date. Very impressive if realized. However, as you said, market do not (or don't want) understand this future picture. Hope they are wrong and we are correct. Miljenko PS: I saw that you have interest in NBIX and VRTX (also both in my holding). To very specific and at the same time very different story, imo.

To: smh who wrote (412)	5/3/1999 11:13:00 PM
From: Miljenko Zuanic	Read Replies (3) \| Respond to of 550

SUGN EU! From: sunday-times.co.uk <<Hence Mr Evans-Freke and Dresdner Kleinwort Benson have just raised an estimated $20 million (£13 million) through a private placing to establish Sugen Europe to seek out and work with European marketing partners. The placing values Sugen Europe at about $100 million - even though it currently has only 15 or so staff, headed by Sam Hamad, another former Bristol-Myers executive.>> So, if SUGN US have ~50% interest in SUGN EU, beside $20 M in finance it is ~$50 M directly more in capitalization. Add to that ~25% for SUGN US from future net drugs sale in EU, it is more than big fat pharma will ever pay for SUGN drugs right in EU. At the end, this venture may show and point to approach which will eliminate pharma bucks as necessity for bt company success and recognition. Not bad. Miljenko